ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ペリンドプリルT-ブチルアミン塩

Perindopril

HCID 107807
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
107133-36-8
標準SMILES
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC
InChIKey
IPVQLZZIHOAWMC-QXKUPLGCSA-N
分子式
C19H32N2O5
平均分子量
368.5 g/mol
単同位体質量
368.23112213

概要

Perindopril is an alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and an antihypertensive agent. It is an ethyl ester, an organic heterobicyclic compound, a dicarboxylic acid monoester and an alpha-amino acid ester. It is a conjugate acid of a perindopril(1-).

名称と識別子

優先名称
Perindopril
IUPAC
(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
現地名
ペリンドプリルT-ブチルアミン塩
英語名
Perindopril erbumine
分子式
C23H43N3O5
分子量
441.61

名称と別名

PERINDOPRIL82834-16-0PerindoprilumMcN-A-2833S-9490DTXSID6023440Y5GMK36KGYCHEBI:8024DTXCID303440(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acidPirindopril(2S,3aS,7aS)-1-((S)-N-((S)-1-Carboxybutyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
名称をさらに表示
ペリンドプリルT-ブチルアミン塩ペリンドプリルエルブミンPERINDOPRIL ERBUMINEペリンドプリルエルブミン (JAN)(2S,3aβ,7aβ)-1-[(S)-2-[[(S)-1-(エトキシカルボニル)ブチル]アミノ]-1-オキソプロピル]オクタヒドロ-1H-インドール-2α-カルボン酸・2-メチル-2-プロパンアミンコバシルペリンドプリルtert-ブチルアミンコバスローペリンドプリル・2-メチル-2-プロパンアミン(2S,3aβ,7aβ)-1-[(S)-2-[[(S)-1-(エトキシカルボニル)ブチル]アミノ]-1-オキソプロピル]オクタヒドロ-1H-インドール-2α-カルボン酸・tert-ブチルアミンペリンドプリル・tert-ブチルアミンペリンシールAceonprindopril APIPerindopril ErbuMine (Aceon)Perindopril t-ButylaMinePerindopril tert-butylamine saltPerindopril for stereochemical purity CRSCoversuMPrestariuMPerindoril

物性

構造計算による物性

XLogP
0.9
極性表面積
95.9 Ų
水素結合供与体数
2
水素結合受容体数
6
回転可能結合数
9
重原子数
26
形式電荷
0
複雑度
524

実験および物理化学的性質

Drugs · 3 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antihypertensives

Pharmaceuticals -> Used in Switzerland

LogP2.6
Solubility1.22e+00 g/L
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Angiotensin-Converting Enzyme Inhibitors; ACE Inhibitors

Pharmaceuticals

Physical DescriptionSolid
Collision Cross Section189.7 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID1044198]

物理化学的性質

融点
126 · 126-128°C
貯蔵温度
2 · 2-8°C
溶解性
2 O: · H2O: 可溶10mg/mL、透明
外見
粉
色
白い
主な用途
医薬品(低分子化合物)
InChIKey
IYNMDWMQHSMDDE-FEWFLNQGNA-N

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

P203, P260, P261, P264+P265, P271, P280, P304+P340, P305+P351+P338, P318, P319, P337+P317, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesEye Irrit. 2 (100%)

毒性情報

HepatotoxicityPerindopril, like other ACE inhibitors, has been associated with a low rate of serum aminotransferase elevations (
Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

perindopril

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Perindopril

0.1

0.4

The usual maintenance dose range is 4 mg to 8 mg administered as a single daily dose or in two divided doses.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 4 mg/day, Lowest Therapeutic Dose (LTD): 0.1 mg/kg-day, and Screening Dose: 0.00002 mg/kg-day.

13-Sep-19

安全データ

化学と産業

薬理情報

ATC Code · 3 件

C09AA04

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingPerindoprilat, 10-20% bound to plasma proteins
Pharmacodynamics · 1 件

Perindopril is a nonsulfhydryl prodrug that is metabolized via first pass effect (62%) and systemic hydrolysis (38%) to perindoprilat, its active metabolite, following oral administration. Perindoprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of perindoprilat by causing increased vasodilation and decreased blood pressure.

Mechanism of Action · 1 件

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Perindoprilat, the active metabolite of perindopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Perindopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

関連反応

21 件
反応記録を作成
HRID 273473 の反応式
HRID 273473反応物として
HRID 273475 の反応式
HRID 273475反応物として
HRID 273477 の反応式
HRID 273477生成物として
HRID 273480 の反応式
HRID 273480生成物として
HRID 273482 の反応式
HRID 273482生成物として
HRID 900395 の反応式
HRID 900395生成物として
HRID 1013436 の反応式
HRID 1013436反応物として
HRID 1180213 の反応式
HRID 1180213生成物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Perinodopril
(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acidS 9490Erbumine, Perindopril1H-Indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,7abeta))-S9490(2S,3aS,7aS)-1-((2S)-2-(((2S)-1-ethoxy-1-oxopentan-2-yl)amino)propanoyl)-octahydro-1H-indole-2-carboxylic acid(2S,3aS,7aS)-1-((2S)-2-(((2S)-1-ethoxy-1-oxopentan-2-yl)amino)propanoyl)octahydro-1H-indole-2-carboxylic acid(2S,3aS,7aS)-1-[(S)-N-[(S)-1-Carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester

データベース識別子

CAS
107133-36-8、82834-16-0
PubChem CID
107807
DTXSID
DTXSID6023440
ChEMBL
CHEMBL1581
ChEBI
CHEBI:8024
UNII
Y5GMK36KGY
EC Number
617-394-0
Nikkaji
J23.744B
SMILES
C(N)(C)(C)C.C(N1[C@@H](C[C@]2([H])CCCC[C@]12[H])C(=O)O)(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC |&1:7,9,15,21,24,r|

化学的性質

化学的特性White Solid

wgk
3
rtecs
NL5999600
hs_code
2933999552
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36
Hazard Classifications
Repr. 2
ストレージクラス
11 - Combustible Solids
Biological Half-LifePerindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.
Metabolism/Metabolites · 2 件

Extensively metabolized, with only 4-12% of the dose recovered in urine following oral administration. Six metabolites have been identified: perindoprilat, perindopril glucuronide, perindoprilat glucuronide, a perindopril lactam, and two perindoprilat lactams. Only perindoprilat is pharmacologically active. Peridoprilat and perindoprilat glucuronide are the two main circulating metabolites.

Perindopril has known human metabolites that include Perindoprilat glucuronide.

FDA Pharmacological Classification · 5 件

Y5GMK36KGY

PERINDOPRIL

Established Pharmacologic Class [EPC] - Angiotensin Converting Enzyme Inhibitor

Mechanisms of Action [MoA] - Angiotensin-converting Enzyme Inhibitors

Perindopril is an Angiotensin Converting Enzyme Inhibitor. The mechanism of action of perindopril is as an Angiotensin-converting Enzyme Inhibitor.

MeSH Pharmacological Classification · 2 件

A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Absorption, Distribution and Excretion · 3 件

Rapidly absorbed with peak plasma concentrations occurring approximately 1 hour after oral administration. Bioavailability is 65-75%. Following absorption, perindopril is hydrolyzed to perindoprilat, which has an average bioavailability of 20%. The rate and extent of absorption is unaffected by food. However, food decreases the extent of biotransformation to peridoprilat and reduces its bioavailability by 35%.

Perindopril is extensively metabolized following oral administration, with only 4 to 12% of the dose recovered unchanged in the urine.

219 - 362 mL/min [oral administration]

Cellular LocationsCytoplasm
Metabolite PathwaysPerindopril Action Pathway

用途と製造

UsesUse (kg; approx.) in Germany (2009): >100
Use ClassificationPharmaceuticals

応用分野

使用An angiotensin-converting enzyme (ACE) inhibitor. Antihypertensive.

一般的な説明Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards

上流・下流製品情報

上流原料

N,N'-ジシクロヘキシルカルボジイミド硫酸水素ロジウム塩化スルフィニル水酸化ナトリウムインドール-2-カルボン酸水素L-ノルバリントリエチルアミンピルビン酸水酸化パラジウム / 炭素1-ヒドロキシベンゾトリアゾール一水和物トルエン-4-スルホン酸

下流製品

(2S,3aS,7aS)-1-[(S)-2-[[(S)-1-カルボキシブチル]アミノ]-1-オキソプロピル]ヘキサヒドロインドリン-2-カルボン酸